Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- PeptiDream and RayzeBio Expand Alliance on Peptide-Radiotherapeutics
August 12, 2022
- Eisai, Lifenet Insurance Enter Capital, Biz Tie-Up to Build Dementia Ecosystem
August 12, 2022
- Opdivo Tops Japan Drug Sales Ranking 7 Months Running: Encise July Data
August 12, 2022
- Moderna Files Omicron Bivalent Vaccine in Japan
August 10, 2022
- Sumitomo Drops 100 Billion Yen Diabetes Sales Goal as Trulicity Collab Ends
August 10, 2022
- Nipro Eyes 60% AG Share in Nexium Generic Market: Exec
August 10, 2022
- Daiichi Sankyo’s HER3 ADC Enters PIII for EGFR-Mutated NSCLC
August 10, 2022
- Yen’s Fall Reaps 10 Billion Yen-Plus Gain on Sales for 5 Japan Makers, Takeda Gets 8.8 Billion Yen: April-June
August 9, 2022
- Pfizer Seeks Japan Nod for Omicron-Adapted Bivalent Jab
August 9, 2022
- Myfembree Snags Endometriosis Nod in US: Myovant/Pfizer
August 9, 2022
- Maruho’s Mitchga Now Available for Eczema Itching in Japan
August 9, 2022
- Chugai Settles Patent Suit against Fresenius Kabi over Alecensa
August 9, 2022
- Enhertu Grabs US Approval for HER2 Low Breast Cancer: Daiichi Sankyo/AZ
August 9, 2022
- Incyte Files Pemazyre for Myelogenous/Lymphatic Tumor in Japan
August 9, 2022
- Sales Rep’s Online Meetings Fall 8.4% YOY in June: Intage
August 9, 2022
- Single-Wholesaler Distribution Unlikely to Constitute Antimonopoly Law Violation: Expert
August 8, 2022
- Kyowa Kirin Chief Sees Late-Stage Assets as Next Japan Biz Drivers, Room for Growth for Duvroq/Crysvita
August 8, 2022
- Eisai’s Q1 Operating Profit Drops 86% on Upfront Payment Receipt in FY2021
August 8, 2022
- 2024 Japan Filing Plan for Oncolytic Virus Unchanged: Oncolys President
August 8, 2022
- Sosei’s Schizophrenia Med Advancing into PII, Triggers US$30 Million from Neurocrine
August 8, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…